Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gauzy To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Gauzy between March 11, 2025 and November 13, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh […]
Toronto, Ontario–(Newsfile Corp. – January 12, 2026) – Quebec Rare Earth Elements Corp. (CSE: QREE) (the “Company“) is pleased to announce that it has entered into an option agreement to acquire the Moose REE Project, a 7km diameter circular magnetic anomaly with a central magnetic core of 2 km in diameter (Exhibit 1). Although minimal
Vancouver, British Columbia–(Newsfile Corp. – January 12, 2026) – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company“), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce the fully subscribed closing of its previously announced non-brokered private placement (the “Offering“), issuing 3,322,153 units (each, a “Unit“) at
Eighteen attorneys from global law firm Greenberg Traurig, LLP have been named to 5280 magazine’s Denver’s Top Lawyers 2026 list, which recognizes the best attorneys in the Mile High City and beyond. 5280 magazine creates annual lists across various industries as resources for businesses and individuals in the Mile High City to find professionals with
The persistent corneal edema market is experiencing steady growth, driven by rising clinical awareness, improved postoperative monitoring, and growing focus on endothelial dysfunction-related complications. Additionally, the launch of emerging therapies such as AURN001 (Aurion Biotech/Alcon), EO2002 (Emmecell), TTHX1114 (Trefoil Therapeutics), and others will further drive the market forward. DelveInsight’s Persistent Corneal Edema Market Insights report
NEW YORK CITY, NY / ACCESS Newswire / January 12, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Zenas and certain of its officers and/or
Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into pregnancy health. Nuvo Intl Group Inc, a leader in remote pregnancy monitoring and AI-enabled maternal-fetal care, today unveiled its pregnancy data solution built from real-world use of its FDA-cleared INVU(TM) pregnancy monitoring wearable technology. Through INVU(TM), Nuvo has assembled what
NEW YORK CITY, NY / ACCESS Newswire / January 12, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. ("Organogenesis" or the "Company") (NASDAQ:ORGO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Organogenesis and certain of its officers and/or
Primis Financial Corp. (NASDAQ: FRST) (the “Company”) today announced that it will release fourth quarter 2025 results after the market closes on Thursday, January 29, 2026. Following the release, the Company will host a conference call and audio webcast for analysts and investors at 10:00 a.m. Eastern Time on Friday, January 30, 2026. The webcast
Vancouver, British Columbia–(Newsfile Corp. – January 12, 2026) – Eastport Critical Metals Corp. (TSXV: EVI) (“Eastport” or the “Company“) is pleased to announce that it has engaged the services of Independent Trading Group (“ITG“) pursuant to an agreement effective December 18, 2026 (the “ITG Agreement“) to provide market-making services in accordance with TSX Venture Exchange (“TSXV“) policies.